Post by Hot Christian Stocks on May 21, 2014 18:25:15 GMT -5
Introducing
Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.
CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, ENDOCAN Corporation, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade development.
Basis & Philosophy
Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.
To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.
Some key phytocannabinoids are:
tetrahydrocannabinol (THC)
cannabidiol (CBD)
cannabigerol (CBG)
cannabichromene (CBC)
cannabinol (CBN)
These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.
The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.
Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.
The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.
While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.
These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.
As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.
Cannabis Science is one of the longest standing companies in the cannabis business.
We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.
Cannabis Science, Inc. is a patient oriented company dedicated to meeting the needs of the community with products based on cannabinoid science, as well as being an advocate for patient rights throughout the world.
What We Do
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
Read More +
Research & Development
Our pursuit of knowledge is done creatively and diligently. Our team of bright minds is always at work to undertake groundbreaking research, and use it to devise new, innovative, and exciting projects, such as medications that can save lives and change a patient’s way of life for the better, and expanding globally so that our positive influence reaches across borders.
Read More +
The Science of Cannabinoids
Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis.
Read More +
Pipeline
See what Cannabis Science has in the works and their progress. These programs will change the lives of many people of all ages, shapes, and sizes, with a variety of illnesses that cannabinoid-based medications can target. These illnesses include cancer, HIV/AIDS, arthritis, chronic pain, and a myriad of others. Click here to see what’s coming down the pipeline!
Read More +
May 21, 2014 Cannabis Science Inc. To Oversee Research For NewColombia Resources
May 20, 2014 Innovation Fuels New Cannabis Based Skin Care Medicines - NEWC's Pharmaceutical Partner in Discussions with City of Medellin
May 15, 2014 Cannabis Based Medicines Gain Traction as Research & Development Ramp up - Company Looks to Develop Topical Cannabis Medicine to Treat Skin Cancer
May 15, 2014 New Colombia Resources Inc. Enters Into a Collaboration Agreement With Farmatech S.A. for Research and Development of Topical Cannabis Based Medicines in Colombia
May 9, 2014 Research & Development Kick Into High Gear For Cannabis Based Medicine - New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
May 9, 2014 New Colombia Resources Inc. Enters into a Collaboration Agreement with the Phoenix Tears Foundation for Research and Development of a Cannabis Based Medicine to Treat Skin Cancer in Colombia.
May 1, 2014 Cannabis Science Supports Patients Out of Time's Eighth National Clinical Conference on Cannabis Therapeutics held May 8-10, 2014 in Portland, Oregon
Apr 30, 2014 Cannabis Science Inc. Signs Agreement With MEDIWIET to Conduct Clinical Observational Study in the Netherlands
Apr 28, 2014 Cannabis Science, Inc. (CBIS) Commends Dr. Sanjay Gupta on His On-Going Contribution to Learning and Educating Regarding the Efficacy of Medical Cannabis for Patients In Need
Apr 25, 2014 Lexaria Announces Managers of Ontario Facility and First Phase Production Plans
CBIS Headlines finance.yahoo.com/q/h?s=CBIS+Headlines
pennystockdivas.com/
Follow on Twitter: twitter.com/PennyStockDivas
Follow on facebook: www.facebook.com/pennystock.divas?fref=ts
Like her facebook page:
www.facebook.com/pages/Penny-Stock-Divas/185908631442850?ref=hl
Disclaimer: pennystockdivas.com is wholly owned by Global Innovator Relations LLC. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Global Innovator Relations, LLC and pennystockdivas.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at pennystockdivas.com/disclaimer Release of Liability: Through use of this website/newsletter viewing or using you agree to hold pennystockdivas.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Pennystockdivas.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Pennystockdivas.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and pennystockdivas.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Pennystockdivas.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Pennystockdivas.com has been compensated $1000 cash for the release of this newsletter and or other marketing services. Pennystockdivas.com, Global Innovator Relations, LLC nor any of its affiliates are not registered investment advisors or broker dealers.